16
total announcements
BALPHARMA.NS · 15 min delayed
Bal Pharma Limited
Bal Pharma Limited has announced the record date for the purpose of dividend payment as September 17, 2026, and communicated to shareholders regarding tax deduction at source (TDS) on final dividend payment.
Bal Pharma Limited
Bal Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026.
Bal Pharma Limited
Bal Pharma Limited has informed the Exchange about the fixation of its 39th Annual General Meeting (AGM) on September 24, 2026, and related dates for dividend payment and e-voting.
Bal Pharma Limited
Bal Pharma Limited has clarified the timeline for utilizing the net proceeds of its preferential issue, stating that it will be done within 18 months from the date of allotment.
Bal Pharma Limited
Bal Pharma Limited has published unaudited financial results for the quarter ended June 30, 2026, and a notice regarding the transfer of unclaimed dividend shares to the Investor Education and Protection Fund Authority.
Bal Pharma Limited
Bal Pharma Limited has announced the outcome of its board meeting, where it approved the unaudited financial results for the quarter ended June 30, 2026, and also approved changes in the designations of two directors, Mr. Ravindra Kumar Kothari and Mr. Virupakshaya Himesh. The company also approved an investment in a joint venture entity in the Philippines and the allotment of 10,00,000 warrants to a promoter on a preferential basis.
Bal Pharma Limited
Bal Pharma Limited has announced its financial results for the period ended June 30, 2026, and other matters from its board meeting. The company has approved the change in designation of two directors, made an investment in a joint venture entity in the Philippines, and allotted 10,00,000 warrants to a promoter at ₹84 per warrant.
Bal Pharma Limited
Bal Pharma Limited has informed the Exchange regarding the voting results of the Postal Ballot conducted through remote e-voting, where 99.96% of the total votes received have approved the issue of 10,00,000 Warrants to the Promoter of the Company on preferential basis.
Bal Pharma Limited
Bal Pharma Limited is providing an opportunity to shareholders to submit comments on the modifications made to the postal ballot notice, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Bal Pharma Limited
Bal Pharma Limited replied to the Exchange's clarification on variations observed between XBRL and PDF financial submissions, confirming that the revised XBRL filings match the PDF financial results and that there has been no change in the financial results approved by the Board of Directors.
Bal Pharma Limited
Bal Pharma Limited has issued a corrigendum to its postal ballot notice dated July 9, 2026, regarding the proposed preferential issue of up to 10,00,000 convertible warrants to a promoter, with a revised issue price of ₹84 per warrant, including a premium of ₹74 per warrant.
Bal Pharma Limited
Bal Pharma Limited has confirmed compliance with SEBI (Depositories and Participants) Regulations, 2018, by submitting details of dematerialized and rematerialized securities to stock exchanges within the prescribed time limit.
Bal Pharma Limited
Bal Pharma Limited has informed the Exchange regarding Notice of Postal Ballot for considering the issue of 10,00,000 Warrants to Mr. Shailesh Siroya, Promoter of the Company on preferential basis.
Bal Pharma Limited
Bal Pharma Limited has informed the Exchange that Mr. Shreepada ML has taken charge as the Company Secretary and Compliance Officer with effect from 23rd June 2026.
Bal Pharma Limited
Bal Pharma Limited has informed the Exchange regarding the closure of the trading window for dealing with the company's securities due to the declaration of unaudited financial results for the quarter ended 30/06/2026.
Bal Pharma Limited
The National Stock Exchange (NSE) has requested clarification from Bal Pharma Limited regarding its financial results for the quarter ended March 31, 2026, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's official response to this request is currently awaited. This indicates potential scrutiny or discrepancies in the reported financial statements.